Crystal Structures of the Histo-Aspartic Protease (HAP) from Plasmodium falciparum

Journal of Molecular Biology

Volumn 388, Issue 3, 2009, Pages 520-540

  Bhaumik, Prasenjit ^a   Xiao, Huogen ^b   Parr, Charity L ^b   Kiso, Yoshiaki ^c   Gustchina, Alla ^a   Yada, Rickey Y ^b   Wlodawer, Alexander ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

aspartic proteases; crystal structure; inhibitor binding

Indexed keywords

APOENZYME; ASPARTIC ACID; ASPARTIC PROTEINASE; GLUTAMIC ACID; HISTIDINE; HISTOASPARTIC PROTEASE; KNI 1006; MONOMER; PEPSTATIN; PLASMEPSIN I; SERINE PROTEINASE; UNCLASSIFIED DRUG; ZINC;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; CRYSTALLIZATION; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

PLASMODIUM FALCIPARUM;

EID: 64649106677     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.03.011     Document Type: Article

References (58)

1. Banerjee R., Liu J., Beatty W., Pelosof L., Klemba M., and Goldberg D.E. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl Acad. Sci. USA 99 (2002) 990-995
2. Ersmark K., Samuelsson B., and Hallberg A. Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev. 26 (2006) 626-666
3. Berry C., Humphreys M.J., Matharu P., Granger R., Horrocks P., Moon R.P., et al. A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum. FEBS Lett. 447 (1999) 149-154
4. Andreeva N., Bogdanovich P., Kashparov I., Popov M., and Stengach M. Is histoaspartic protease a serine protease with a pepsin-like fold?. Proteins 55 (2004) 705-710
5. Bjelic S., and Aqvist J. Computational prediction of structure, substrate binding mode, mechanism, and rate for a malaria protease with a novel type of active site. Biochemistry 43 (2004) 14521-14528
6. Xiao H., Sinkovits A.F., Bryksa B.C., Ogawa M., and Yada R.Y. Recombinant expression and partial characterization of an active soluble histo-aspartic protease from Plasmodium falciparum. Protein Expression Purif. 49 (2006) 88-94
7. Parr C.L., Tanaka T., Xiao H., and Yada R.Y. The catalytic significance of the proposed active site residues in Plasmodium falciparum histoaspartic protease. FEBS J. 275 (2008) 1698-1707
8. Umezawa H., Aoyagi T., Morishima H., Matsuzaki M., and Hamada M. Pepstatin, a new pepsin inhibitor produced by actinomycetes. J. Antibiot. (Tokyo) 23 (1970) 259-262
9. Nezami A., Kimura T., Hidaka K., Kiso A., Liu J., Kiso Y., et al. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 42 (2003) 8459-8464
10. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
11. Jaskolski M., Gilski M., Dauter Z., and Wlodawer A. Stereochemical restraints revisited: how accurate are refinement targets and how much should protein structures be allowed to deviate from them?. Acta Crystallogr., Sect. D: Biol. Crystallogr. 63 (2007) 611-620
12. Wlodawer A., Minor W., Dauter Z., and Jaskolski M. Protein crystallography for non-crystallographers or how to get the best (but not more) from the published macromolecular structures. FEBS J. 275 (2008) 1-21
13. Dunn B.M. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev. 102 (2002) 4431-4458
14. Erskine P.T., Coates L., Mall S., Gill R.S., Wood S.P., Myles D.A., and Cooper J.B. Atomic resolution analysis of the catalytic site of an aspartic proteinase and an unexpected mode of binding by short peptides. Protein Sci. 12 (2003) 1741-1749
15. Asojo O.A., Gulnik S.V., Afonina E., Yu B., Ellman J.A., Haque T.S., and Silva A.M. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J. Mol. Biol. 327 (2003) 173-181
16. Clemente J.C., Govindasamy L., Madabushi A., Fisher S.Z., Moose R.E., Yowell C.A., et al. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallogr., Sect. D: Biol. Crystallogr. 62 (2006) 246-252
17. Cohen G.E. ALIGN: a program to superimpose protein coordinates, accounting for insertions and deletions. J. Appl. Crystallogr. 30 (1997) 1160-1161
18. Asojo O.A., Afonina E., Gulnik S.V., Yu B., Erickson J.W., Randad R., et al. Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 Å in complex with the inhibitors rs367 and rs370. Acta Crystallogr., Sect. D: Biol. Crystallogr. 58 (2002) 2001-2008
19. Sali A., Veerapandian B., Cooper J.B., Moss D.S., Hofmann T., and Blundell T.L. Domain flexibility in aspartic proteinases. Proteins 12 (1992) 158-170
20. Abad-Zapatero C., Rydel T.J., and Erickson J. Revised 2.3 Å structure of porcine pepsin: evidence for a flexible subdomain. Proteins 8 (1990) 62-81
21. Andreeva N.S., and Pechik I.V. Comparison of three-dimensional structures of flexible protein molecules. Mol. Biol. (Moscow) 29 (1995) 1102-1113
22. Gilliland G.L., Winborne E.L., Nachman J., and Wlodawer A. The three-dimensional structure of recombinant bovine chymosin at 2.3 Å resolution. Proteins 8 (1990) 82-101
23. Safro M.G., and Andreeva N.S. On the role of peripheral interactions in specificity of chymosin. Biochem. Int. 20 (1990) 555-561
24. Gustchina E., Rumsh L., Ginodman L., Majer P., and Andreeva N. Post X-ray crystallographic studies of chymosin: the existence of two structural forms and the regulation of activity by the interaction with the histidine-proline cluster of kappa-casein. FEBS Lett. 379 (1996) 60-62
25. Istvan E.S., and Goldberg D.E. Distal substrate interactions enhance plasmepsin activity. J. Biol. Chem. 280 (2005) 6890-6896
26. Prade L., Jones A.F., Boss C., Richard-Bildstein S., Meyer S., Binkert C., and Bur D. X-ray structure of plasmepsin II complexed with a potent achiral inhibitor. J. Biol. Chem. 280 (2005) 23837-23843
27. Omara-Opyene A.L., Moura P.A., Sulsona C.R., Bonilla J.A., Yowell C.A., Fujioka H., et al. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J. Biol. Chem. 279 (2004) 54088-54096
28. Mimoto T., Imai J., Tanaka S., Hattori N., Kisanuki S., Akaji K., and Kiso Y. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem. Pharm. Bull. (Tokyo) 39 (1991) 3088-3090
29. Mimoto T., Imai J., Tanaka S., Hattori N., Takahashi O., Kisanuki S., et al. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. Chem. Pharm. Bull. (Tokyo) 39 (1991) 2465-2467
30. Kiso Y. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Biopolymers 40 (1996) 235-244
31. Maegawa H., Kimura T., Arii Y., Matsui Y., Kasai S., Hayashi Y., and Kiso Y. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic. Bioorg. Med. Chem. Lett. 14 (2004) 5925-5929
32. Abdel-Rahman H.M., Kimura T., Hidaka K., Kiso A., Nezami A., Freire E., et al. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biol. Chem. 385 (2004) 1035-1039
33. Kimura T., Nguyen J.T., Maegawa H., Nishiyama K., Arii Y., Matsui Y., et al. Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 3276-3280
34. Nguyen J.T., Zhang M., Kumada H.O., Itami A., Nishiyama K., Kimura T., et al. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors. Bioorg. Med. Chem. Lett. 18 (2008) 366-370
35. Zhang M., Nguyen J.T., Kumada H.O., Kimura T., Cheng M., Hayashi Y., and Kiso Y. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme. Bioorg. Med. Chem. 16 (2008) 6880-6890
36. Zhang M., Nguyen J.T., Kumada H.O., Kimura T., Cheng M., Hayashi Y., and Kiso Y. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties. Bioorg. Med. Chem. 16 (2008) 5795-5802
37. Hidaka K., Kimura T., Ruben A.J., Uemura T., Kamiya M., Kiso A., et al. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg. Med. Chem. 16 (2008) 10049-10060
38. Fitzgerald P.M.D., McKeever B.M., VanMiddlesworth J.F., Springer J.P., Heimbach J.C., Leu C.T., et al. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0 Å resolution. J. Biol. Chem. 265 (1990) 14209-14219
39. Oefner C., Binggeli A., Breu V., Bur D., Clozel J.P., D'Arcy A., et al. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?. Chem. Biol. 6 (1999) 127-131
40. Boss C., Corminboeuf O., Grisostomi C., Meyer S., Jones A.F., Prade L., et al. Achiral, cheap, and potent inhibitors of plasmepsins I, II, and IV. ChemMedChem 1 (2006) 1341-1345
41. Hof F., Schutz A., Fah C., Meyer S., Bur D., Liu J., et al. Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV. Angew. Chem., Int. Ed. Engl. 45 (2006) 2138-2141
42. Barrett A.J., Rawlings N.D., and Woessner J.F. Handbook of Proteolytic Enzymes (2004), Elsevier Academic Press, Amsterdam, The Netherlands
43. Pearl L., and Blundell T. The active site of aspartic proteinases. FEBS Lett. 174 (1984) 96-101
44. Andreeva N.S., and Rumsh L.D. Analysis of crystal structures of aspartic proteinases: on the role of amino acid residues adjacent to the catalytic site of pepsin-like enzymes. Protein Sci. 10 (2001) 2439-2450
45. Wlodawer A., Miller M., Jaskólski M., Sathyanarayana B.K., Baldwin E., Weber I.T., et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245 (1989) 616-621
46. Miller M., Jaskólski M., Rao J.K.M., Leis J., and Wlodawer A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 337 (1989) 576-579
47. Remaut H., Bompard-Gilles C., Goffin C., Frere J.M., and Van Beeumen J. Structure of the Bacillus subtilis d-aminopeptidase DppA reveals a novel self-compartmentalizing protease. Nat. Struct. Biol. 8 (2001) 674-678
48. Fujinaga M., Chernaia M.M., Tarasova N.I., Mosimann S.C., and James M.N. Crystal structure of human pepsin and its complex with pepstatin. Protein Sci. 4 (1995) 960-972
49. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26 (1993) 795-800
50. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 50 (1994) 760-763
51. Keegan R.M., and Winn M.D. MrBUMP: an automated pipeline for molecular replacement. Acta Crystallogr., Sect. D: Biol. Crystallogr. 64 (2008) 119-124
52. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30 (1997) 1022-1025
53. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr., Sect. D: Biol. Crystallogr. 57 (2001) 1373-1382
54. Matthews B.W. Solvent content of protein crystals. J. Mol. Biol. 33 (1968) 491-497
55. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 (1997) 240-255
56. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 (2004) 2126-2132
57. Krissinel E., and Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 (2004) 2256-2268
58. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, San Carlos, CA